Download PDF
Pneumologie 2014; 68(10): 653-661
DOI: 10.1055/s-0034-1377412
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Impfungen in der Pneumologie[*]

Vaccinations in Pneumology
C. Forstner
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
2   Universitätsklinik für Innere Medizin I, Klinische Abteilung für Infektionskrankheiten und Tropenmedizin, Medizinische Universität Wien
,
M. W. Pletz
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
› Author Affiliations
Further Information

Publication History

eingereicht10 April 2014

akzeptiert nach Revision15 May 2014

Publication Date:
07 October 2014 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die effektivste Maßnahme zur Prävention von Infektionen des Respirationstrakts ist der Einsatz von Schutzimpfungen gegen wichtige respiratorische Pathogene. Aufgrund ihrer großen klinischen Relevanz wird die Vakzinierung gegenüber Pneumokokken, Influenza A/B-Virus und Bordetella pertussis nicht nur im Kindesalter, sondern auch im Erwachsenenalter von der Ständigen Impfkommission am Robert Koch Institut empfohlen. In der vorliegenden Übersichtsarbeit werden die klinische Bedeutung und Sicherheit der entsprechenden Impfungen anhand der aktuellen Datenlage als auch die Vor- und Nachteile der unterschiedlichen verfügbaren Impfstoffe diskutiert.

Abstract

The best measure to prevent infections of the respiratory tract is the use of vaccines against important respiratory tract pathogens. The Standing Vaccination Committee at the Robert Koch Institute recommends not only children but also adult vaccination against pneumococci, influenza A/B and Bordetella pertussis, because of a high disease burden. In the present review the clinical significance and safety of those vaccinations as well as advantages and disadvantages of the currently available vaccines are discussed.

* Professor Hartmut Lode zum 75. Geburtstag gewidmet.


 

  • Literatur

  • 1 Robert Koch Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epid Bull 2013; 34: 313-334
    PubMedGoogle Scholar
  • 2 Lode H, Ludwig E, Kassianos G. Pneumococcal infection – low awareness as a potential barrier to vaccination: results of a European study. Adv Ther 2013; 30: 387-405
    CrossrefPubMedGoogle Scholar
  • 3 Beel ER, Rench MA, Montesinos DP et al. Acceptability of immunization in adult contacts of infants: Possibility of expanding platforms to increase adult vaccine uptake. Vaccine 2014; 32: 2540-2545
    CrossrefPubMedGoogle Scholar
  • 4 Lode H. Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies. Intensive Care Med 2009; 35: 391-393
    CrossrefPubMedGoogle Scholar
  • 5 Pletz MW, Rohde G, Schutte H et al. Epidemiology and Aetiology of Community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 2011; 136: 775-780
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Varon E, Mainardi JL, Gutmann L. Streptococcus pneumoniae: still a major pathogen. Clin Microbiol Infect 2010; 16: 401
    CrossrefPubMedGoogle Scholar
  • 7 Schmidt-Ioanas M, Lode H. Treatment of pneumonia in elderly patients. Expert Opin Pharmacother 2006; 7: 499-507
    CrossrefPubMedGoogle Scholar
  • 8 Aliberti S, Mantero M, Mirsaeidi M et al. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 2014; 20 (Suppl. 05) 52-58
    PubMedGoogle Scholar
  • 9 Forstner C, Plefka S, Tobudic S et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 2012; 30: 5449-5452
    CrossrefPubMedGoogle Scholar
  • 10 Rose M, Lode H, de Roux A et al. Pneumococcal vaccination in obstructive lung diseases – what can we expect?. Dtsch Med Wochenschr 2005; 130: 461-465
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Lee H, Kim J, Tagmazyan K. Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines. Am Fam Physician 2013; 88: 655-663 , 663B-F
    PubMedGoogle Scholar
  • 12 Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154
    CrossrefPubMedGoogle Scholar
  • 13 Rodrigo C, Lim WS. The relevance of pneumococcal serotypes. Curr Infect Dis Rep 2014; 16: 403
    CrossrefPubMedGoogle Scholar
  • 14 Johnson HL, Deloria-Knoll M, Levine OS et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7: e1000348
    CrossrefPubMedGoogle Scholar
  • 15 Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014; 58: 854-864
    CrossrefPubMedGoogle Scholar
  • 16 Harboe ZB, Benfield TL, Valentiner-Branth P et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010; 50: 329-337
    CrossrefPubMedGoogle Scholar
  • 17 Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J 2010; 36: 712-713
    CrossrefPubMedGoogle Scholar
  • 18 de Roux A, Lode H. Pneumococcal vaccination. Eur Respir J 2005; 26: 982-983
    CrossrefPubMedGoogle Scholar
  • 19 Pletz MW, Maus U, Krug N et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206
    CrossrefPubMedGoogle Scholar
  • 20 de Roux A, Schmöle-Thoma B, Silber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023
    CrossrefPubMedGoogle Scholar
  • 21 Sigurdardottir ST, Center KJ, Davidsdottir K et al. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Vaccine 2014; 32: 417-424
    CrossrefPubMedGoogle Scholar
  • 22 Musher DM, Manoff SB, McFetridge RD et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919-928
    CrossrefPubMedGoogle Scholar
  • 23 Moberley S, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422
    PubMedGoogle Scholar
  • 24 Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9: 213-220
    CrossrefPubMedGoogle Scholar
  • 25 Clutterbuck EA, Lazarus R, Yu LM et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect 2012; 205: 1408-1416
    CrossrefPubMedGoogle Scholar
  • 26 Lazarus R, Clutterbuck E, Yu LM et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52: 736-742
    CrossrefPubMedGoogle Scholar
  • 27 Weil Olivier C. Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children. Med Mal Infect 2013; 43: 309-321
    CrossrefPubMedGoogle Scholar
  • 28 Azzari C, Martinon-Torres F, Schmitt HJ et al. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice. Pediatr Infect Dis 2014; 33: 858-864
    CrossrefPubMedGoogle Scholar
  • 29 Ludwig E, Unal S, Bogdan M et al. Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults. Cent Eur J Public Health 2013; 21: 233-236
    PubMedGoogle Scholar
  • 30 Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis 2012; 55: 816-824
    CrossrefPubMedGoogle Scholar
  • 31 Pletz MW, Maus U, Hohlfeld JM et al. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance. Dtsch Med Wochenschr 2008; 133: 358-362
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
    CrossrefPubMedGoogle Scholar
  • 33 Link-Gelles R, Taylor T, Moore MR et al. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013; 31: 2572-2577
    CrossrefPubMedGoogle Scholar
  • 34 Pletz MW, Ewig S, Lange C et al. Update Pneumonie 2012. Dtsch Med Wochenschr 2012; 137: 2265-2284
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Centers for Diease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-819
    PubMedGoogle Scholar
  • 36 Sächsische Impfkommission. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. Im Internet: http://www.gesunde.sachsen.de/download/lua/LUA_HM_Impfempfehlungen_E1.pdf Stand: 01.01.2014
    PubMedGoogle Scholar
  • 37 Leroux-Roels G, Maes C, De Boever F et al. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine DOI: 10.1016/j.vaccine.2014.02.052.
    PubMedGoogle Scholar
  • 38 Mann B, Thornton J, Heath R et al. Broadly protective protein-based pneumococcal vaccine comprised of pneumolysin-toxoid-CbpA peptide recombinant fusion protein. J Infect Dis 2014; 209: 1116-1125
    CrossrefPubMedGoogle Scholar
  • 39 Bresee J, Hayden FG. Epidemic Influenza - Responding to the expected but unpredictable. New Engl J Med 2013; 368: 589-592
    CrossrefPubMedGoogle Scholar
  • 40 Metersky ML, Masterton RG, Lode H et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012; 16: e321-e331
    PubMedGoogle Scholar
  • 41 Rothberg MB, Haessler DS. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38 (Suppl. 04) e91-e97
    CrossrefPubMedGoogle Scholar
  • 42 Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993; 90: 4171-4175
    CrossrefPubMedGoogle Scholar
  • 43 Mertz D, Kim TH, Johnstone J et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013; 347: f5061
    CrossrefPubMedGoogle Scholar
  • 44 Centers for Disease Control and Prevention. Persons at risk for medical complications due to influenza. Im Internet: www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm#at-risk [Stand: 20. 08. 2013]
    PubMedGoogle Scholar
  • 45 Naleway AL, Henkle EM, Ball S et al. Barriers and facilitator to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control 2014; 42: 371-375
    CrossrefPubMedGoogle Scholar
  • 46 White LF, Archer B, Pagano M. Determing the dynamics of influenza transmission by age. Emerg Themes Epidemiol 2014; 11: 4
    CrossrefPubMedGoogle Scholar
  • 47 Ferdinands JM, Olsho LE, Agan AA et al. Effectiveness on influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014; 210: 674-683
    CrossrefPubMedGoogle Scholar
  • 48 Tessmer A, Welte T, Schmidt-Ott R et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 2011; 38: 147-153
    CrossrefPubMedGoogle Scholar
  • 49 Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009; 27: 1101-1110
    CrossrefPubMedGoogle Scholar
  • 50 Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361: 1260-1267
    CrossrefPubMedGoogle Scholar
  • 51 Prutsky GJ, Domecg JP, Elraiyah T et al. Assessing the evidence: live attenuated influenza vaccine in children younger than 2 years. A systematic review. Pediatr Infect Dis J 2014; 33: e106-e115
    CrossrefPubMedGoogle Scholar
  • 52 Barr IG, Russell C, Besselaar TG et al. Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014. WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014; 32: 4713-4725
    CrossrefPubMedGoogle Scholar
  • 53 Jain VK, Rivera L, Zaman K et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013; 369: 2481-2491
    CrossrefPubMedGoogle Scholar
  • 54 Kieninger D, Sheldon E, Lin WY et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013; 13: 343
    CrossrefPubMedGoogle Scholar
  • 55 Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207: 1878-1887
    CrossrefPubMedGoogle Scholar
  • 56 Centers for Disease Control and Prevention. CDC advisory committee recommends an influenza vaccine option for persons with egg allergy. Im Internet: www.cdc.gov/media/releases /2013/a0620-FluBlok.html ; Stand: 21.06.2013
    PubMedGoogle Scholar
  • 57 Jin J. 2014 adult immunization schedule: recombinant flu vaccine expands options for people with egg allergies. JAMA 2014; 311: 893
    PubMedGoogle Scholar
  • 58 Baldo V, Baldovin T, Pellegrini M et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010: 517198
    PubMedGoogle Scholar
  • 59 Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 2013; 42: 159-174
    PubMedGoogle Scholar
  • 60 Zimmermann RK, Lin CJ, Ross T et al. Randomized clinical trial of high-dose influenza vaccine in nursing home residents (Abstract). IDWeek. 2013: 576b Im Internet: https://idsa.confex.com/idsa/2013/webprogram/Paper43076.html [Stand: 03. 10. 2013]
    PubMedGoogle Scholar
  • 61 Young F, Marra R. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29: 8788-8801
    CrossrefPubMedGoogle Scholar
  • 62 Mannino S, Villa M, Apolone G et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176: 527-533
    CrossrefPubMedGoogle Scholar
  • 63 De Roux A, Marx A, Burkhardt O et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006; 24: 1537-1542
    CrossrefPubMedGoogle Scholar
  • 64 Eckerle I, Rosenberger KD, Zwahlen M et al. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013; 8: e56974
    CrossrefPubMedGoogle Scholar
  • 65 Demicheli V, Jefferson T, Al-Ansary LA et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014; 3: CD001269
    PubMedGoogle Scholar
  • 66 Avery RK. Influenza vaccines in the setting of solid-organ transplantation: are they safe?. Curr Opin Infect Dis 2012; 25: 464-468
    CrossrefPubMedGoogle Scholar
  • 67 Persson I, Granath F, Askling J et al. Risk of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population-and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014; 275: 172-190
    CrossrefPubMedGoogle Scholar
  • 68 Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7: e33536
    CrossrefPubMedGoogle Scholar
  • 69 Ahmed SS, Schur PH, Macdonald NE et al. Narcolepsy, 2009 A (H1N1) pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity and vaccine adjuvants. J Autoimmun 2014; 50C: 1-11
    PubMedGoogle Scholar
  • 70 Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013; 25: 164-170
    CrossrefPubMedGoogle Scholar
  • 71 Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-1206
    CrossrefPubMedGoogle Scholar
  • 72 Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11: 2020-2030
    CrossrefPubMedGoogle Scholar
  • 73 Smith AM, Adler FR, Ribeiro RM et al. Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 2013; 9: e1003238
    CrossrefPubMedGoogle Scholar
  • 74 Kash JC, Walters KA, Davis AS et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2011; 2: e00172-11
    PubMedGoogle Scholar
  • 75 Plotkin SA. The pertussis problem. Clin Infect Dis 2014; 58: 830-833
    CrossrefPubMedGoogle Scholar
  • 76 Chiappini E, Stival A, Galli L et al. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013; 13: 151
    CrossrefPubMedGoogle Scholar
  • 77 Hellenbrand W. Keuchhusten-Erkrankungen in den neuen Bundesländern, 2002 bis 2012. Epid Bull 2014; 1: 1-11 http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/01/Art_01.html
    PubMedGoogle Scholar
  • 78 Robert Koch Institut. Pertussis (Keuchhusten) RKI-Ratgeber für Ärzte. Im Internet: http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Pertussis.html [Stand: 26. 06. 2013]
    PubMedGoogle Scholar
  • 79 Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353: 1555-1563
    CrossrefPubMedGoogle Scholar
  • 80 Witt MA, Arias L, Katz PH et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56: 1248-1254
    CrossrefPubMedGoogle Scholar
  • 81 Klein NP, Bartlett J, Fireman B et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131: e1716-e1722
    CrossrefPubMedGoogle Scholar
  • 82 Knuf M, Zepp F, Meyer C et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006; 24: 2043-2048
    CrossrefPubMedGoogle Scholar
  • 83 Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new?. Trend Microbiol 2012; 20: 211-213
    CrossrefPubMedGoogle Scholar
  • 84 Thorstensson R, Trollfors B, Al-Tawil N et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PloS One 2014; 9: e83449
    CrossrefPubMedGoogle Scholar